Results 251 to 260 of about 488,286 (382)

What are set and setting: Reducing vagueness to improve research and clinical practice. [PDF]

J Psychopharmacol
Patch K, Smith WR.
europepmc   +1 more source

Lactose enemas plus placebo tablets vs. neomycin tablets plus starch enemas in acute portal systemic encephalopathy

, 1981
Misael Uribe, Jesús Moreno Bérthier, Hilel Lewis, Juan M. Mata, Jose G. Sierra, Guillermo García‐Ramos, Javier Ramírez Acosta, Margarita Dehesa   +7 more
openalex   +1 more source

Terfenadine and placebo compared in the treatment of chronic idiopathic urticaria: a randomised double‐blind study. [PDF]

, 1985
Jamie Ferguson, K. A. Macdonald, K. Kenicer   +2 more
openalex   +1 more source

Pregabalin dependence, withdrawal, suicidality and psychosis reports: A disproportionality analysis of the Australian adverse events database

British Journal of Clinical Pharmacology, EarlyView.
Aims Globally, Australia has the highest per capita consumption rate of pregabalin, commonly prescribed for neuropathic pain. Emerging evidence suggests pregabalin may be associated with the onset or recurrence of several potentially life‐threatening psychiatric events in some individuals.
Amy G. McNeilage, Ali Gholamrezaei, Bridin Murnion, Suzanne Nielsen, Claire E. Ashton‐James   +4 more
wiley   +1 more source

Justice for Placebo: Placebo Effect in Clinical Trials and Everyday Practice. [PDF]

Medicines (Basel)
Knezevic NN, Sic A, Worobey S, Knezevic E.   +3 more
europepmc   +1 more source

An experimental medicine protocol for exploring the haemodynamic effects of dual agonism at the glucagon‐like peptide‐1 and glucagon receptor in healthy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims Glucagon‐like peptide‐1 (GLP‐1) and glucagon dual receptor agonists are in clinical development for a range of metabolic conditions, including type 2 diabetes and obesity. The cardiovascular actions at these receptors are well studied, but less is known about their combination.
James Goodman, Victoria E. Parker, Carmel M. McEniery, Giovanni Di Stefano, Annette Hubsch, Evangelia Vamvaka, Jo Helmy, Fotini Kaloyirou, Navazh Jalaludeen, Peter Barker, Lutz Jermutus, Joseph Cheriyan, Philip Ambery, Ian B. Wilkinson   +13 more
wiley   +1 more source

Open-Label Placebos as Adjunct for the Preventive Treatment of Migraine: A Randomized Clinical Trial.

JAMA Netw Open
Kleine-Borgmann J, Schmidt K, Ludwig L, Schulz M, Holle-Lee D, Gaul C, Bingel U.   +6 more
europepmc   +1 more source

Revolutionizing Chinese medicine granule placebo with a machine learning four-color model. [PDF]

Chin Med
Teng T, Zhang J, Miao P, Liang L, Song X, Liu D, Zhang J.   +6 more
europepmc   +1 more source

Ketanserin in essential hypertension: a double-blind, placebo-controlled study

, 1985
H A Cameron, L E Ramsay
openalex   +1 more source

Population pharmacokinetic modelling revealed large variability in oromucosal absorption of Δ9‐tetrahydrocannabinol in older patients with poor appetite

British Journal of Clinical Pharmacology, EarlyView.
Aim Cannabis‐based medicines are gaining interest and being explored for new therapeutic indications, many of which commonly affect older medical patients. As most previous studies of the population pharmacokinetics of cannabinoids have been performed in healthy adults, this study aimed to investigate the population pharmacokinetics of Δ9 ...
Ida Klitzing Storgaard, Rikke Lundsgaard Nielsen, Morten Baltzer Houlind, Olivia Bornæs, Louise Westberg Strejby Christensen, Aino Leegaard Andersen, Helle Gybel Juul‐Larsen, Lillian Mørch Jørgensen, Torben Breindahl, Baker Nawfal Jawad, Izzet Altintas, Ove Andersen, Trine Meldgaard Lund   +12 more
wiley   +1 more source